MariaTGrosse-PerdekampMD

Oncology • Urbana, IL

Breast Cancer, Gynecologic Cancer, Hematologic Oncology

Medical Oncologist/Hematologist

Join to view full profile

Dr. Grosse-Perdekamp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grosse-Perdekamp's full profile

Already have an account?

Office
509 W University Ave
Urbana, IL 61801
Phone+1 217-383-3010

Education & Training

Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003
Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 2000
Albert Ludwigs University Faculty of MedicineClass of 1995

Certifications & Licensure

IL State Medical License 2003 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Oxybutynin Chloride in Managing Hot Flashes Start of enrollment: 2016 Dec 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia
Matthew S. Lee, Sanjivani Sathe, Srijan Valasapalli, Maria Grosse Perdekamp
Cureus. 2021-11-09
29 citations
Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.
Kathryn J. Ruddy, Jennifer Le-Rademacher, Mario E. Lacouture, Mary Wilkinson, Adedayo A. Onitilo
Breast. 2019-12-01

Other Languages

German